Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Figure 2

ROC curve analyses of NGAL and CA19-9 for the diagnosis of cholangiocarcinoma. The diagnostic accuracy of each biomarker, in terms of its sensitivity and specificity, is presented by receiver operating characteristic (ROC) curve analysis.